Source link : https://newshealth.biz/health-news/second-menin-inhibitor-approved-for-mutated-r-r-aml/
Two phase 3 trials will study Kura Oncology’s ziftomenib for frontline acute myeloid leukemia, one with venetoclax and the other with standard induction/consolidation. Medscape Medical News Source link : https://www.medscape.com/viewarticle/second-menin-inhibitor-approved-mutated-r-r-aml-2025a1000vl7?src=rss Author : Publish date : 2025-11-13 18:23:00 Copyright for syndicated content belongs to the linked Source.
The post Second Menin Inhibitor Approved for Mutated R/R AML first appeared on News Health.
—-
Author : News Health
Publish date : 2025-11-13 18:23:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8